Intellectus Partners’s Sarepta Therapeutics SRPT Stock Holding History

Intellectus Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-425	Closed	-$51K	–	371
2019 Q1	$51K	Buy	+425	New	+$54.6K	0.02%	257

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Intellectus Partners's SRPT Position: Q2 2019 in Review

Intellectus Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 425 shares — an estimated $51K sold.

Intellectus Partners first reported a position in SRPT in Q1 2019 and held it in 1 quarter. The position peaked at $51K in Q1 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

Intellectus Partners reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
Intellectus Partners sold 425 Sarepta Therapeutics shares in Q2 2019, an estimated $51K.
Intellectus Partners first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 1 quarter.
Intellectus Partners's Sarepta Therapeutics position peaked at $51K in Q1 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Intellectus Partners's 13F filing for Q2 2019, filed 8 Aug 2019.